Lenvatinib/everolimus improves survival better than everolimus alone in metastatic renal cell cancer.
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D004357:Drug Synergism; D000068338:Everolimus / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000473:pathology; D010671:Phenylurea Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*; D016019:Survival Analysis
D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011804:Quinolines; D000068338:Everolimus; C531958:lenvatinib